New Prepandrix data from GSK

UK drug major GlaxoSmithKline presented new data on its Prepandrix H5N1 vaccine at the European Influenza Conference in Vilamoura, Portugal.

The data suggest the adjuvanted pre-pandemic influenza vaccine confers broad cross-clade immunity that is maintained until a second dose many months later, even if the subsequent dose is formulated from a different strain of H5N1 influenza.

The results are from two Phase II, open, randomized studies in adults aged 18 to 60 years old. In the first, a single booster dose of Prepandrix was administered six months after primary vaccination with either one or two doses of the same adjuvanted vaccine. GSK says the results show that two vaccination doses, either six-months or 21-days apart, elicit a comparable immune response against the vaccine strain.